Zacks Research Brokers Boost Earnings Estimates for JNJ

Johnson & Johnson (NYSE:JNJ) – Stock analysts at Zacks Research upped their Q3 2026 earnings per share (EPS) estimates for Johnson & Johnson in a research report issued on Tuesday, September 9th. Zacks Research analyst Team now expects that the company will post earnings of $2.91 per share for the quarter, up from their previous estimate of $2.88. The consensus estimate for Johnson & Johnson’s current full-year earnings is $10.58 per share. Zacks Research also issued estimates for Johnson & Johnson’s Q4 2026 earnings at $2.89 EPS, FY2026 earnings at $11.29 EPS, Q1 2027 earnings at $2.87 EPS, Q2 2027 earnings at $3.08 EPS and FY2027 earnings at $12.17 EPS.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the previous year, the firm earned $2.82 earnings per share. Johnson & Johnson’s revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS.

Several other analysts have also issued reports on JNJ. Guggenheim reaffirmed a “neutral” rating and issued a $167.00 target price (up previously from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Barclays upped their target price on Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 17th. Royal Bank Of Canada upped their target price on Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a research note on Thursday, July 17th. Wall Street Zen lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Friday, September 5th. Finally, Morgan Stanley upped their target price on Johnson & Johnson from $171.00 to $176.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $176.29.

Johnson & Johnson Stock Down 0.6%

Shares of JNJ opened at $177.12 on Wednesday. The firm has a market cap of $426.57 billion, a P/E ratio of 18.94, a P/E/G ratio of 2.27 and a beta of 0.40. The stock has a 50 day simple moving average of $169.51 and a two-hundred day simple moving average of $161.02. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $181.16.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is 55.61%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Johnson & Johnson

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. NWF Advisory Services Inc. raised its holdings in shares of Johnson & Johnson by 69.6% during the second quarter. NWF Advisory Services Inc. now owns 9,850 shares of the company’s stock valued at $1,505,000 after acquiring an additional 4,041 shares in the last quarter. Prospera Capital Management LLC raised its holdings in shares of Johnson & Johnson by 12.5% during the second quarter. Prospera Capital Management LLC now owns 1,868 shares of the company’s stock valued at $285,000 after acquiring an additional 208 shares in the last quarter. SevenBridge Financial Group LLC raised its holdings in shares of Johnson & Johnson by 4.3% during the second quarter. SevenBridge Financial Group LLC now owns 45,124 shares of the company’s stock valued at $6,893,000 after acquiring an additional 1,880 shares in the last quarter. V. M. Manning & CO. Inc. bought a new position in shares of Johnson & Johnson during the second quarter valued at approximately $311,000. Finally, Osaic Holdings Inc. raised its holdings in shares of Johnson & Johnson by 13.2% during the second quarter. Osaic Holdings Inc. now owns 691,594 shares of the company’s stock valued at $106,457,000 after acquiring an additional 80,518 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.